Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BRTXQNASDAQ:GHNYSE:HIMSNASDAQ:OPCH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRTXQBioRestorative Therapies$1.65-3.4%$1.73$0.00▼$0.06$2.71B102.3662.17 million shs44,669 shsGHGuardant Health$50.03+0.3%$44.82$20.14▼$52.92$6.18B1.372.14 million shs2.00 million shsHIMSHims & Hers Health$46.37+12.0%$49.65$13.47▼$72.98$9.27B2.0922.77 million shs64.15 million shsOPCHOption Care Health$32.00+0.7%$32.05$21.39▼$35.53$5.21B0.741.87 million shs1.20 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRTXQBioRestorative Therapies-3.44%-2.94%-0.60%-9.84%-22.17%GHGuardant Health+0.26%-1.07%+27.73%+15.97%+70.23%HIMSHims & Hers Health+12.00%-24.10%-13.15%+59.31%+115.06%OPCHOption Care Health+0.66%+1.39%-0.37%-7.86%+13.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBRTXQBioRestorative TherapiesN/AN/AN/AN/AN/AN/AN/AN/AGHGuardant Health3.7853 of 5 stars2.53.00.04.32.02.50.6HIMSHims & Hers Health2.3481 of 5 stars2.03.00.00.01.73.31.9OPCHOption Care Health3.6575 of 5 stars2.43.00.04.22.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBRTXQBioRestorative Therapies 0.00N/AN/AN/AGHGuardant Health 3.00Buy$53.767.46% UpsideHIMSHims & Hers Health 1.92Reduce$39.58-14.63% DownsideOPCHOption Care Health 2.88Moderate Buy$35.5010.94% UpsideCurrent Analyst Ratings BreakdownLatest BRTXQ, HIMS, GH, and OPCH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025HIMSHims & Hers HealthTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$45.006/23/2025HIMSHims & Hers HealthCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell ➝ Sell6/23/2025HIMSHims & Hers HealthUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$30.006/23/2025HIMSHims & Hers HealthUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderperform ➝ Underperform6/23/2025HIMSHims & Hers HealthNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold6/18/2025OPCHOption Care HealthJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$36.006/13/2025GHGuardant HealthMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$60.00 ➝ $65.006/11/2025HIMSHims & Hers HealthMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight ➝ Equal Weight$40.006/4/2025HIMSHims & Hers HealthNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$61.00 ➝ $65.005/7/2025HIMSHims & Hers HealthDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/6/2025HIMSHims & Hers HealthUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMixed ➝ Mixed(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBRTXQBioRestorative Therapies$110K24,594.39N/AN/A($0.68) per share-2.43GHGuardant Health$739.02M8.39N/AN/A($1.13) per share-44.27HIMSHims & Hers Health$1.48B7.03$0.39 per share117.59$2.16 per share21.47OPCHOption Care Health$5.00B1.05$1.66 per share19.33$8.25 per share3.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBRTXQBioRestorative Therapies-$12.52M-$1.07N/A∞N/AN/AN/AN/AN/AGHGuardant Health-$436.37M-$3.39N/AN/AN/A-53.82%-1,200.44%-26.77%8/6/2025 (Estimated)HIMSHims & Hers Health$126.04M$0.6967.2089.171.569.24%22.75%15.51%8/4/2025 (Estimated)OPCHOption Care Health$211.82M$1.2425.8125.401.924.12%16.90%7.00%7/30/2025 (Estimated)Latest BRTXQ, HIMS, GH, and OPCH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025HIMSHims & Hers Health$0.12$0.20+$0.08$0.20$535.21 million$586.01 million4/30/2025Q1 2025GHGuardant Health-$0.57-$0.49+$0.08-$0.77$189.91 million$203.47 million4/29/2025Q1 2025OPCHOption Care Health$0.36$0.40+$0.04$0.28$1.26 billion$1.33 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBRTXQBioRestorative TherapiesN/AN/AN/AN/AN/AGHGuardant HealthN/AN/AN/AN/AN/AHIMSHims & Hers HealthN/AN/AN/AN/AN/AOPCHOption Care HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBRTXQBioRestorative TherapiesN/AN/AN/AGHGuardant HealthN/A4.113.76HIMSHims & Hers HealthN/A1.591.32OPCHOption Care Health0.821.541.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBRTXQBioRestorative TherapiesN/AGHGuardant Health92.60%HIMSHims & Hers Health63.52%OPCHOption Care Health98.05%Insider OwnershipCompanyInsider OwnershipBRTXQBioRestorative Therapies12.20%GHGuardant Health6.10%HIMSHims & Hers Health13.71%OPCHOption Care Health0.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBRTXQBioRestorative Therapies71.64 billionN/ANot OptionableGHGuardant Health2,021123.89 million116.33 millionNot OptionableHIMSHims & Hers Health1,637223.83 million193.15 millionOptionableOPCHOption Care Health8,088163.75 million162.70 millionOptionableBRTXQ, HIMS, GH, and OPCH HeadlinesRecent News About These CompaniesBTSG vs. OPCH: Which Home Infusion Stock is a Better Buy Now?June 26 at 4:00 PM | zacks.comOption Care Health to Announce Second Quarter 2025 Financial Results and Host Conference CallJune 25 at 4:19 PM | globenewswire.comOption Care Health’s Q1 Earnings Call: Our Top 5 Analyst QuestionsJune 23, 2025 | finance.yahoo.comOption Care Health, Inc. (NASDAQ:OPCH) Shares Sold by Avior Wealth Management LLCJune 22, 2025 | marketbeat.comSG Americas Securities LLC Makes New Investment in Option Care Health, Inc. (NASDAQ:OPCH)June 21, 2025 | marketbeat.comRiverbridge Partners LLC Has $50.64 Million Stock Holdings in Option Care Health, Inc. (NASDAQ:OPCH)June 20, 2025 | marketbeat.comJanney Capital Management LLC Purchases New Position in Option Care Health, Inc. (NASDAQ:OPCH)June 20, 2025 | marketbeat.comOption Care Health (NASDAQ:OPCH) Earns "Market Outperform" Rating from JMP SecuritiesJune 20, 2025 | americanbankingnews.comOption Care Health, Inc. (NASDAQ:OPCH) Receives $35.50 Average Price Target from BrokeragesJune 20, 2025 | americanbankingnews.com1OPCH : Forecasting The Future: 5 Analyst Projections For Option Care HealthJune 18, 2025 | benzinga.comJMP Securities Reaffirms "Market Outperform" Rating for Option Care Health (NASDAQ:OPCH)June 18, 2025 | marketbeat.comOption Care Health, Inc. (NASDAQ:OPCH) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 17, 2025 | marketbeat.comAssenagon Asset Management S.A. Lowers Position in Option Care Health, Inc. (NASDAQ:OPCH)June 15, 2025 | marketbeat.comFort Washington Investment Advisors Inc. OH Trims Holdings in Option Care Health, Inc. (NASDAQ:OPCH)June 13, 2025 | marketbeat.comHere’s Why Option Care Health (OPCH) Surged in Q1June 12, 2025 | msn.comGAMMA Investing LLC Acquires 110,776 Shares of Option Care Health, Inc. (NASDAQ:OPCH)June 12, 2025 | marketbeat.comHarbor Capital Advisors Inc. Reduces Position in Option Care Health, Inc. (NASDAQ:OPCH)June 11, 2025 | marketbeat.comOption Care Health, Inc. (NASDAQ:OPCH) Shares Sold by Wedge Capital Management L L P NCJune 10, 2025 | marketbeat.com12,062 Shares in Option Care Health, Inc. (NASDAQ:OPCH) Acquired by Squarepoint Ops LLCJune 7, 2025 | marketbeat.comUnpacking Q1 Earnings: Option Care Health (NASDAQ:OPCH) In The Context Of Other Senior Health, Home Health & Hospice StocksJune 5, 2025 | msn.comTwo Sigma Investments LP Purchases 99,070 Shares of Option Care Health, Inc. (NASDAQ:OPCH)June 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingAmong the Market’s Most Shorted: 2 Firms With +40% Short InterestBy Leo Miller | June 3, 2025View Among the Market’s Most Shorted: 2 Firms With +40% Short InterestWhy Super Micro Computer's Upside Could Trigger a Short SqueezeBy Gabriel Osorio-Mazilli | June 3, 2025View Why Super Micro Computer's Upside Could Trigger a Short Squeeze3 Penny Stocks Analysts Believe Are Headed HigherBy Chris Markoch | June 4, 2025View 3 Penny Stocks Analysts Believe Are Headed HigherApplied Digital: Now the High-Stakes Race to Build BeginsBy Jeffrey Neal Johnson | June 17, 2025View Applied Digital: Now the High-Stakes Race to Build BeginsBRTXQ, HIMS, GH, and OPCH Company DescriptionsBioRestorative Therapies OTCMKTS:BRTXQ$1.65 -0.06 (-3.44%) As of 06/25/2025BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company's two core programs are related to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow, and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc and treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The company have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100to treat persistent lower back pain due to painful degenerative discs. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy in preclinical stage to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). In addition, the company provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York. On March 20, 2020, BioRestorative Therapies, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of New York.Guardant Health NASDAQ:GH$50.03 +0.13 (+0.26%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$50.58 +0.55 (+1.09%) As of 05:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.Hims & Hers Health NYSE:HIMS$46.37 +4.96 (+11.97%) Closing price 06/26/2025 03:59 PM EasternExtended Trading$47.01 +0.65 (+1.39%) As of 05:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.Option Care Health NASDAQ:OPCH$32.00 +0.21 (+0.66%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$31.96 -0.04 (-0.14%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. Option Care Health, Inc. is headquartered in Bannockburn, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
